Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
ConclusionPatients treated with eptinezumab demonstrated persistency that was higher than subcutaneous anti-CGRP mAbs and similar to onabotulinumtoxinA.Graphical Abstract
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research
More News: Chronic Pain | Genetics | Headache | Insurance | Migraine | Neurology | Pain | Statistics | Study